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We conducted a prospective study of 312 patients (194 with multiple myeloma,
118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous
hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and
MASP2 genes were investigated and serial measurements of serum concentrations
of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities
of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were
taken before conditioning chemotherapy, before HSCT and once weekly after (totally
4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation.
The results were compared with data from 267 healthy controls and analyzed
in relation to clinical data to explore possible associations with cancer and with
chemotherapy-induced medical complications. We found a higher frequency of MBL
deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients
compared with controls. It was however not associated with hospital infections or
post-HSCT recovery of leukocytes, but seemed to be associated with the most
severe infections during follow-up. Paradoxically, high MBL serum levels were a
risk factor for prolonged fever and some infections. The first possible association
of MBL2 gene 3′-untranslated region polymorphism with cancer (lymphoma) in
Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was
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relatively frequent in lymphoma patients who experienced bacteremia during hospital
stay. The median concentration of CL-LK was higher in myeloma patients compared
with healthy subjects. Chemotherapy induced marked increases in serum MBL and
MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in
CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections
following chemotherapy of myeloma and lymphoma have been reported. Here we found
no evidence for an association between MBL deficiency and infection during the short
period of neutropenia following conditioning treatment before HSCT. However, we noted
a possible protective effect of MBL during follow-up, and suspected that to be fully
effective when able to act in combination with phagocytic cells after their recovery.
Keywords: CL-LK, collectin, complement, hematopoietic stem cell transplantation (HSCT), mannose-binding
lectin (MBL), MASP, mutliple myeloma, lymphoma
INTRODUCTION
Hematological cancers derive from various cells of the immune
system. Multiple myeloma (MM), a plasma cell malignancy,
is relatively common. It more often affects males than
females and is usually diagnosed at age >55 years. Although
incurable, treatment strategies including chemotherapy followed
by autologous hematopoietic stem cell transplantation (auto-
HSCT) allow marked prolongation of patients’ life expectancy
(1–5). The term “lymphoma” includes a variety of highly
heterogeneous lymphoid malignancies. Hodgkin’s lymphoma
(HL) accounts for approximately 1/10 of all lymphomas at
diagnosis. It is characterized by giant, multinucleated Reed-
Sternberg and large mononuclear Hodgkin’s cells (of B cell
lineage). Incidence of HL peaks during early adulthood (20–
34 years) and again at age >60 years; it is slightly commoner
in males, and most newly diagnosed patients are successfully
cured (6–9). Non-Hodgkin’s lymphomas (NHL) are also more
often diagnosed in men than in women (10–15). NHL usually
arise from the B cells lineage (>40 subtypes; >80% of cases)
although some T cell and NK cell lymphomas occur. Some NHL
are histologically aggressive with a high mortality rate, but NHL
are often curable when diagnosed and treated early.
Hematological malignancies obviously compromise the host
immune response. Intensive chemotherapy and/or radiotherapy,
adds further immunosuppression (mostly due to profound and
prolonged neutropenia). High-dose chemotherapy and auto-
HSCT is the standard first-line treatment for younger patients
with multiple myeloma as well as standard second-line treatment
in patients with Hodgkin’s lymphoma and aggressive non-
Hodgkin’s lymphomas (1, 6, 10, 16).
Due to severe immunocompromise caused by both the disease
and therapy, patients are at a high risk of morbidity andmortality
due to infections. It is estimated that up to 80% of patients have
fever, andmore than one third suffer fromwell-defined infections
(17–19). Septicemia is the commonest type of infection, and
some patients are affected by pneumonia or alimentary tract
Abbreviations:DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin’s lymphoma;
HSCT, hematopoietic stem cell transplantation; LYMPH, lymphoma; MM,
multiple myeloma; NHL, non-Hodgkin’s lymphoma.
infections (19). Post-HSCT reconstitution of bone marrow after
conditioning therapy is usually attained in ∼3 weeks, but full
recovery of functional leukocytes takes longer (20, 21). During
the period of aplasia, patients have to be isolated, carefully
monitored and receive prophylactic/supportive medication (4,
18, 22).
Complement is a complex system of numerous components
that constitutes a crucial branch of the immune response.
It protects from a variety of infections and takes part
in clearance of host cells undergoing apoptosis, necrosis
or neoplastic transformation. However, dysregulation of its
activation may result in chronic or systemic inflammation and
possibly promotion of tumor growth. Therefore, involvement of
complement may have opposing effects in cancer. Furthermore,
some of its components may be considered as candidate
diagnostic or prognostic biomarkers of the disease (23, 24).
Pattern recognition molecules known to activate complement
via the lectin pathway are two collectins [mannose-binding lectin
(MBL) and CL-LK, composed of two peptides: collectin-10 (CL-
10, CL-L1) and collectin-11 (CL-11, CL-K1)] and ficolins (ficolin-
1,-2,-3). They form complexes with MASP (MBL-associated
serine proteases: MASP-1,-2,-3) and non-enzymatic related
proteins (MAp19, MAp44) (25–27).
The aim of our investigation was to estimate possible
association of complement-activating collectins (MBL, CL-LK)
and associated serine proteases with cancer (MM, LYMPH) itself
and with hospital infections after chemotherapy followed by
auto-HSCT.
Single-nucleotide polymorphisms, localized to codons 52
(A/D), 54 (A/B), and 57 (A/C) of the first exon of the
MBL2 gene, influence both MBL serum level and its activity.
The variant, dominant alleles (collectively designated O), are
associated with lower MBL levels compared with the A (wild-
type) one. Furthermore, promoter region polymorphisms (H/L
and Y/X at positions−550 and−221, respectively) also determine
MBL concentration to some extent, due to influence on gene
expression. The O/O and LXA/O genotypes are considered to be
associated with primary MBL deficiency [reviewed in (24)].
The role of MBL and clinical associations of its deficiency
apparently depend on clinical context, patient’s age, co-existence
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of other defects of the immune system, etc. Several reports and
review papers suggested that MBL2 A/O heterozygosity may
be advantageous for the host. Relative high frequency of such
genotypes in a variety of populations has been suspected to result
from an evolutionary, selective trend (28–31). It was observed
that MBL2 O alleles (and especially O/O genotypes) are less
common among centenarians than in general population. On
the other hand, in this age group, a relatively low frequency of
high MBL-producing haplotypes/genotypes was found. Similar
trends were noted in octo- and nonagenarians (32, 33). Therefore,
it was postulated that moderate MBL serum concentration may
be favorable to healthy aging while both MBL deficiency and
its hyper-reactivity may be deleterious for the host. The first
was related to variety of infectious which, especially when
severe or recurrent, may lead to the worsening of quality of
life and therefore to shortening of life expectancy. On the
other hand, high MBL may favor autoimmunity and/or promote
tumorigenesis. The latter is often associated with cachexia and
fatal outcome. That issue becomes even more complicated when
some opposing effects are considered: MBL deficiency may be
a risk factor for development of cancer (like childhood acute
lymphoblastic leukemia) while high MBL may facilitate some
intracellular pathogens to enter their target cells [reviewed in
(24, 33)].
Originally, Peterslund et al. (34) found a strong relationship
between MBL deficiency and serious infections in a relatively
small group of patients suffering from hematological
malignancies (n = 54, including 18 with MM and 13 with
NHL). Many subsequent studies failed to reproduce the strength
of this relationship although positive results were reported in
some studies but not others. It is clear that MBL does not have a
universal role in preventing infections following chemotherapy,
but any influence or lack of it is still controversial. Further studies
are therefore needed and should be carried out prospectively
with substantial numbers of patients. We have investigated
a large (n = 194) series of multiple myeloma patients and
compared them with a more heterogeneous group of lymphoma
patients (n = 118), as well as healthy controls (n = 267). In
addition to MBL, we have also extended our investigations to
include CL-LK and MASP-2 since those factors are also relevant
to collectin-mediated complement activation.
MATERIALS AND METHODS
Patients and Controls
Three hundred and twelve patients suffering from hematological
malignancies, undergoing auto-HSCTwere recruited. This group
included 194 persons diagnosed with multiple myeloma (MM;
95 females and 99 males; mean age: 58.9 ± 8.9 years), 27 with
Hodgkin’s lymphoma (HL; 6 females and 21 males; mean age:
40.8 ± 13.7) and 91 with non-Hodgkin’s lymphomas (NHL;
40 females, 51 males; mean age: 51.6 ± 11.9). For analyses,
HL and NHL groups were combined to form LYMPH (n
= 118; mean age: 49.3 ± 13.1). The NHL group included
patients with diffuse large B-cell lymphoma (DLBCL, n = 31),
mantle cell lymphoma (MCL, n = 18), follicular lymphoma
(FL, n = 13), Waldenström’s macroglobulinemia (WM, n =
TABLE 1 | Basic characterisation of patients and controls.
Group
Multiple
myeloma (MM)
Lymphoma
(LYMPH)
Control
(C)
N 194 118 267
Sex (F/M) 95/99 46/72 174/93
Age (years)
mean ± SD
range
58.9 ± 8.9
25-71
49.3 ± 13.1
21–73
48 ± 13
18–84
Conditioning therapy
(n)
MEL-200 (156)
MEL-140 (19)
MEL-100 (7)
Radiotherapy
alone (12)
BEAM (88)
BeAM (12)
Bendamustine (4)
CTX (13)
TBC (1)
Not applicable
Complications (n)
Infections
with bacteremia
with no bacteremia
Febrile neutropenia
None of above
74
45
30
39
81
72
35
38
10
36
Not applicable
1), non-follicular (diffuse) lymphoma, unspecified (NFL, n =
21), marginal-zone lymphoma (mucosa-associated lymphoid
tissue lymphoma, MALTL, n = 1), anaplastic large cell
lymphoma, kinase negative (ALCL ALK-, n = 1), anaplastic
large cell lymphoma, kinase positive (ALCL ALK+, n = 1),
angioimmunoblastic T-cell lymphoma (AITL, n = 2), peripheral
T-cell lymphoma (PTCL, n= 1), hepatosplenic T-cell lymphoma
(HSTL, n = 1). In total, the group of patients included 141
females and 171 males; mean age was 55.2 ± 11.7 years;
age range: 21–73). Basic demographic data are summarized in
Table 1.
With the exception of 12 persons suffering from MM
undergoing radiotherapy alone, patients were treated with
conditioning high-dose chemotherapy before transplantation
(Table 1). In 28 patients (24 LYMPH and 4MM), both
chemotherapy and radiotherapy were used. Standard treatment
for multiple myeloma was MEL-200 (melphalan at dosage 200
mg/m2) although in some instances lower doses (MEL-140,
MEL-100) were administered. The majority of LYMPH patients
were treated with BEAM: carmustine (300 mg/m2), etoposide
(800 mg/m2), cytarabine (1600 mg/m2), melphalan (140 mg/m2),
accompanied, or not by radiotherapy. For the remaining,
BeAM (carmustine replaced with bendamustine), bendamustine
(alone or accompanied by radiation), cyclophosphamide (CTX)
and radiotherapy or TBC combination (thiotepa, busulfan,
cyclophosphamide) were used (Table 1).
During hospital stay, crucial clinical parameters like white
blood cell (WBC) count, absolute neutrophil count (ANC),
platelet (PLT) count, inflammatory markers [C-reactive protein
(CRP), fibrinogen (FBG), and procalcitonin (PCT)] levels
and incidence of complications [infections (associated with
bacteremia or not), febrile neutropenia (FN); duration of fever
>38◦C] were recorded and used for analyses. Etiological agents
of infections are listed in Supplementary Table 1.
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One hundred age-matched controls (unrelated volunteers
with no history of cancer, autoimmune diseases, or recurrence
of infections) were recruited. Furthermore, DNA/serum samples
from 167 healthy adult subjects collected for our previous
projects were used, therefore control group included 267
individuals (174 females and 93 males; mean age: 48 ± 13; age
range: 18–84). Basic data are presented in Table 1. The study
was approved by the Ethics Committee of the Medical University
of Lodz. The written informed consent from patients/controls
was obtained. This work conforms to the provisions of the
Declaration of Helsinki.
Blood and Serum Samples
Blood samples for DNA extraction were taken into citrated tubes
before chemotherapy and stored at −80◦C. DNA was extracted
with the use of GeneMATRIX Quick Blood Purification Kit
(EURx Ltd, Gdansk, Poland), according to the manufacturer’s
protocol. Samples for serum isolation were taken into tubes with
clot activator before chemotherapy (sample 1), before HSCT
(sample 2; usually 3–7 days later) and once weekly till hospital
discharge (sample 3: usually 7 days after HSCT; mean 7.0 ± 0.8;
sample 4: usually 14 days after HSCT; mean 13.6 ± 1.2; in some
patients sample 5: 21 days after HSCT; mean 20.3 ± 2). Sixty-
three patients were additionally sampled∼45 days (mean 45.3
± 7.6; sample 45) while 59 were additionally sampled at ∼100
days (mean 104.1± 19.3; sample 100) after HSCT, during control
examination. Among them, 40 persons were sampled at “45” and
“100” points. Sera were stored at−80◦C until testing.
MBL2 Genotyping
Promoter (H/L, at position−550, rs11003125 and Y/X, at
position−221, rs7096206) and exon 1 (A/D, codon 52, rs5030737;
A/B, codon 54, rs1800450, and A/C, codon 57, rs1800451)
single nucleotide polymorphisms of the MBL2 gene were
investigated as previously described (35). SNPs of the same
gene, located within the 3
′
-untranslated region of the exon 4:
Ex4-1483 T>C (rs10082466), Ex4-1260 C>T (rs56009657), Ex4-
1067 G>A (rs10824792), Ex4-1064 G>T (rs35327474), Ex4-
1063 G>T (rs35768126), Ex4-1047 T>G (rs12254577), Ex4-
939 T>C (rs774307463), Ex4-901 A>G (rs2120132), Ex4-879
A>C (rs2120131), Ex4-845 C>T (rs2165813), Ex4-718 G>T
(rs2099903) and Ex4-710 A>G (rs2099902) were investigated
by direct sequencing. Briefly, PCRs were run on a C1000
Thermal Cycler (Bio-Rad, Hercules, CA, USA), using appropriate
spanning primers (designed with the use of PRIMER3 software,
http://bioinfo.ut.ee/primer3/):
forward: 5′-TTTCCCCATGGTTTTAATCTG-3′,
reverse: 5′-TCACTAAAACCACCAAAACAAGA-3′,
under the following conditions: 96◦C for 5min, then 35
cycles (96◦C for 40 s, 60◦C for 30 s, 72◦C for 45 s) and finally
72◦C for 5min. The PCR products were purified with the help
of EPPiC - Enzymatic Post-PCR Immediate Cleanup (A&A
Biotechnology, Gdynia, Poland). Samples thus prepared were
directly used as templates for sequencing, performed using
the GeneAnalizer-3000 sequencer (Applied Biosystems, Foster
City, CA, USA), reverse primer, BrightDyeTerminator Cycle
Sequencing kit (NimaGen BV, Nijmegen, The Netherlands) and
TABLE 2 | Frequency of MBL2 genotypes (SNP located within promoter and exon
1) within major groups.
Genotype Group
C MM LYMPH
A/A 180 (69.5) 132 (68) 80 (67.8)
YA/O 53 (20.5) 29 (14.9) 24 (20.3)
XA/O or O/O 26 (10) 33 (17)* 14 (11.9)
Percentages are shown in parentheses. *p = 0.034; OR 1.84; 95%CI (1.06-3.19) (vs. C).
BDX64 Sequencing Enhancement Buffer (MCLab, San Francisco,
CA, USA) according to themanufacturer’s instructions. Sequence
electropherograms were visually inspected to confirm base
calling at the SNP sites using novoSNP (36).
MASP2 Genotyping
The presence of missense mutation +359 A>G (Asp120Gly)
located within exon 3 of the MASP2 gene, rs72550870) was
investigated with the use of PCR-RFLP method, as described
previously (37).
For an investigation of +1111 A>C (exon 10, Asp371Tyr,
rs12711521) polymorphism, the PCR-RFLP procedure was
employed. PCR reactions were run on a C1000 Thermal Cycler
(Bio-Rad), using primers designed with the use of PRIMER3
software:
forward: 5′-TTATTTTCAGACCATGGGGG-3′,
reverse: 5′-TCTGGGTGGTTTCAAATTCC-3′.
The following conditions were applied: 95◦C for 3min, then
35 cycles (95◦C for 30 s, 61◦C for 20 s and 72◦C for 30 s), followed
by a final elongation (72◦C for 5min). After that, the PCR
products were treated with MboI enzyme (Fermentas), (37◦C,
2 h). The digestion products were further analyzed on a 6%
polyacrylamide gel. The PCR product (522 bp) corresponding to
C variant has two digestion sites while that corresponding to A
allele has only one. Consequently, the first underwent cleavage
into three (286, 176, and 60 bp) while the second was cleaved into
two (286 and 237 bp) fragments.
MBL Quantification and Determination of
MBL-MASP Activity
MBL concentration/activity was measured by ELISA based on
binding to solid-phase mannan and detection using monoclonal
anti-human MBL antibody (HYB131-1, BioPorto Diagnostics,
Copenhagen, Denmark) as previously described (38). MBL-
MASP-1 complex activity (39, 40) and MBL-MASP-2 activity
(40, 41), were measured using a fluorescence method and an
ELISA, respectively. VPR-AMC peptide (Bachem, Bubendorf,
Switzerland) was used as the substrate for MASP-1 (39). Rabbit
polyclonal anti-human C4c Abs (Dako, Glostrup, Denmark)
and corresponding goat HRP-conjugated secondary antibodies
(Dako) were used for detection of deposited C4 products after
incubation of the serum sample on mannan-coated wells, for
an estimation of MBL-MASP-2 complex activity (40). MBL
deficiency was taken as 150 ng/ml (42, 43). “High” MBL
concentration (>3000 ng/ml) was chosen based on the value
Frontiers in Immunology | www.frontiersin.org 4 September 2018 | Volume 9 | Article 2153
S´wierzko et al. Collectins and MASP in Auto-HSCT
T
A
B
L
E
3
|
F
re
q
u
e
n
c
y
o
f
M
B
L
2
g
e
n
o
ty
p
e
s
(S
N
P
lo
c
a
te
d
w
ith
in
e
xo
n
4
3
′ -
U
T
R
)
w
ith
in
m
a
jo
r
g
ro
u
p
s.
G
e
n
o
ty
p
e
P
o
ly
m
o
rp
h
is
m
G
ro
u
p
E
x
4
-7
1
0
E
x
4
-7
1
8
E
x
4
-8
4
5
E
x
4
-8
7
9
E
x
4
-9
0
1
E
x
4
-9
3
9
E
x
4
-1
0
4
7
E
x
4
-1
0
6
3
E
x
4
-1
0
6
4
E
x
4
-1
0
6
7
E
x
4
-1
2
6
0
E
x
4
-1
4
8
3
C
(n
=
2
5
5
)
M
M
(n
=
1
9
4
)
LY
M
P
H
(n
=
1
1
8
)
g
t1
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/T
G
/G
G
/G
A
/A
C
/C
T
/T
9
5
(3
7
.2
)
5
9
(3
0
.4
)
2
8
(2
3
.7
)*
g
t2
A
/G
G
/T
C
/T
A
/C
A
/G
T
/T
T
/T
G
/G
G
/G
A
/G
C
/C
T
/C
6
6
(2
5
.9
)
4
4
(2
2
.7
)
4
0
(3
3
.9
)
g
t3
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/T
G
/G
G
/G
A
/G
C
/C
T
/T
4
7
(1
8
.4
)
4
0
(2
0
.6
)
2
9
(2
4
.6
)
g
t4
A
/G
G
/T
C
/T
A
/C
A
/G
T
/T
T
/T
G
/G
G
/G
G
/G
C
/C
T
/C
1
5
(5
.9
)
1
7
(8
.8
)
6
(5
.1
)
g
t5
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/T
G
/G
G
/G
G
/G
C
/C
T
/T
9
(3
.5
)
8
(4
.1
)
4
(3
.4
)
g
t6
G
/G
T
/T
T
/T
C
/C
G
/G
T
/T
T
/T
G
/G
G
/G
G
/G
C
/C
C
/C
8
(3
.1
)
9
(4
.6
)
3
(2
.5
)
g
t7
A
/A
G
/G
C
/C
A
/A
A
/A
T
/C
T
/T
G
/G
G
/G
A
/A
C
/C
T
/T
4
(1
.6
)
2
(1
)
3
(2
.5
)
g
t8
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/T
G
/G
G
/G
G
/G
C
/T
T
/T
2
(0
.8
)
0
0
g
t9
A
/G
G
/T
C
/T
A
/C
A
/G
T
/T
T
/T
G
/G
G
/G
G
/G
C
/C
T
/T
1
(0
.4
)
2
(1
)
0
g
t1
0
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/T
G
/T
G
/T
G
/G
C
/C
T
/T
1
(0
.4
)
1
(0
.5
)
0
g
t1
1
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/T
G
/T
G
/T
A
/G
C
/C
T
/T
1
(0
.4
)
0
1
(0
.8
)
g
t1
2
A
/A
G
/G
C
/T
A
/C
A
/G
T
/T
T
/T
G
/G
G
/G
A
/G
C
/C
T
/T
1
(0
.4
)
0
0
g
t1
3
A
/G
G
/T
C
/T
A
/C
A
/G
T
/T
T
/T
G
/G
G
/G
A
/G
C
/C
T
/T
1
(0
.4
)
1
(0
.5
)
2
(1
.7
)
g
t1
4
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/T
G
/G
G
/G
G
/G
C
/C
T
/C
1
(0
.4
)
0
0
g
t1
5
A
/G
G
/G
C
/C
A
/A
A
/G
T
/T
T
/T
G
/G
G
/G
A
/G
C
/C
T
/C
1
(0
.4
)
0
0
g
t1
6
G
/G
T
/T
T
/T
C
/C
G
/G
T
/T
T
/T
G
/G
G
/G
G
/G
C
/C
T
/C
1
(0
.4
)
1
(0
.5
)
0
g
t1
7
A
/G
G
/T
C
/T
A
/C
A
/G
T
/C
T
/T
G
/G
G
/G
A
/G
C
/C
T
/C
1
(0
.4
)
1
(0
.5
)
1
(0
.8
)
g
t1
8
A
/G
G
/T
C
/T
A
/C
A
/G
T
/T
T
/T
G
/G
G
/G
A
/A
C
/C
T
/T
0
1
(0
.5
)
0
g
t1
9
A
/A
G
/G
C
/C
A
/A
A
/A
T
/C
T
/T
G
/G
G
/G
A
/G
C
/C
T
/T
0
1
(0
.5
)
0
g
t2
0
A
/G
G
/T
C
/T
A
/C
A
/G
T
/T
T
/T
G
/T
G
/T
G
/G
C
/C
T
/C
0
1
(0
.5
)
0
g
t2
1
A
/G
G
/G
C
/T
A
/C
A
/G
T
/T
T
/T
G
/G
G
/G
A
/G
C
/C
T
/C
0
1
(0
.5
)
0
g
t2
2
G
/G
G
/G
T
/T
C
/C
G
/G
T
/T
T
/T
G
/G
G
/G
G
/G
C
/C
C
/C
0
1
(0
.5
)
0
g
t2
3
A
/A
G
/G
C
/C
A
/A
G
/G
T
/T
T
/T
G
/T
G
/T
A
/G
C
/C
T
/T
0
1
(0
.5
)
0
g
t2
4
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/G
A
/A
A
/A
C
/C
C
/C
T
/T
0
1
(0
.5
)
0
g
t2
5
A
/G
G
/T
C
/T
A
/C
A
/G
T
/T
T
/T
A
/G
A
/C
C
/T
C
/T
T
/C
0
1
(0
.5
)
0
g
t2
6
A
/G
G
/T
C
/T
A
/C
A
/G
T
/T
T
/T
A
/G
A
/C
C
/T
C
/C
C
/C
0
1
(0
.5
)
0
g
t2
7
A
/A
G
/G
C
/C
A
/A
A
/A
T
/T
T
/T
A
/A
A
/A
C
/C
C
/T
T
/T
0
0
1
(0
.8
)
P
e
rc
e
n
ta
g
e
s
a
re
s
h
o
w
n
in
p
a
re
n
th
e
s
e
s
.
D
iff
e
re
n
c
e
s
in
c
o
m
p
a
ri
s
o
n
w
it
h
g
t1
a
re
m
a
rk
e
d
in
re
d
.
* p
=
0
.0
1
;
O
R
0
.5
2
;
9
5
%
C
I
(0
.3
2
-0
.8
6
)
(v
s
.
C
).
Frontiers in Immunology | www.frontiersin.org 5 September 2018 | Volume 9 | Article 2153
S´wierzko et al. Collectins and MASP in Auto-HSCT
TABLE 4 | Frequency of MASP2 genotypes (corresponding to polymorphisms
+359 A>G and +1111 A>C SNP) within major groups.
Group Polymorphism
+359 A/G +1111 A>C
C A/A: 233 (90) A/A: 179 (69.6)
A/G: 26 (10) A/C: 69 (26.8)
G/G: – C/C: 9 (3.5)
MM A/A: 175 (90.2) A/A: 125 (64.4)
A/G: 19 (9.8) A/C: 65 (33.5)
G/G: – C/C: 4 (2.1)
LYMPH A/A: 101 (85.6) A/A: 91 (77.1)
A/G: 17 (14.4) A/C: 26 (22)*
G/G: – C/C: 1 (0.8)*
Percentages are shown in parentheses. *Number of C allele carriers (A/C or C/C genotype)
significantly lower in comparison with MM patients: p = 0.023; OR 1.86; 95% CI
(1.11-3.13).
corresponding to the 95th percentile determined for the control
group (2978 ng/ml). For MBL-MASP-1 or-2 complex activities,
the value of 1 U/ml was arbitrarily assigned for the standard
serum (38, 40).
Assay for CL-LK
CL-LK concentration was determined by sandwich TRIFMA, as
described (44). Mouse anti-human CL-10 monoclonal antibody
(clone 4F97D) was used for coating while biotinylated rabbit
anti-human CL-10 mAb (clone P1), followed by Eu3+-labeled
streptavidin (Perkin Elmer, Waltham, MA, USA) was used for
detection. “Low” and “high” CL-LK levels were arbitrarily defined
as <242 ng/ml (corresponding to the 10th percentile within
control group) and >583 ng/ml (95th percentile determined for
controls), respectively.
Assay for MASP-2
MASP-2 levels were determined by TRIFMA, as described by
Moller-Kristensen et al. (45), with slight modification (37). Rat
antibodies of clone 8B were used for coating, while those of
clone 6G12 (biotinylated) were used for detection. “Low” and
“high” MASP-2 levels (based on 10 and 95th percentiles within C
group) were arbitrarily defined as <172 ng/ml and >627 ng/ml,
respectively.
Statistical Analysis
The Statistica (version 13.1, Dell Poland) software package
was used for data management and statistical calculations. The
medians of protein concentrations were compared using the
Mann-Whitney U-test. It was chosen because MBL, MASP-
2, MBL-MASP-1, and MBL-MASP-2 values were not normally
distributed (not shown). The same test was employed for CL-
LK (normally distributed), to make the analyses comparable.
Changes during hospital stay and after discharge were analyzed
by Friedman’s ANOVA test. The frequencies of low or high
levels, as well as genotypes/alleles were compared by two-
sided Fischer’s exact test (or χ2 when appropriate). Correlations
FIGURE 1 | Mannose-binding lectin serum concentrations in patients (before
conditioning chemotherapy) and controls. Blue bars present median values
(given below group descriptions). (A) controls (C) vs. multiple myeloma (MM)
patients; (B) controls vs. lymphoma (LYMPH) patients. MM-A, LYMPH-A:
patients who experienced infections with proven bacteremia; MM-B,
LYMPH-B: patients who experienced infections with no bacteremia; MM-C,
LYMPH-C: patients who experienced febrile neutropenia; MM-D, LYMPH-D:
patients who experienced none of afore-mentioned complications during
hospital stay.
were determined by Spearman’s test. P <0.05 were considered
statistically significant.
RESULTS
MBL2 Gene Polymorphisms Located
Within Promoter Region and Exon 1
The frequency of A/A homozygotes was similar in MM, LYMPH
and C groups. However, MBL deficiency-associated genotypes
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(LXA/O, O/O) were significantly more common in patients with
multiple myeloma (Table 2). Those genotypes did not appear
in the short term (2–3 weeks after HSCT) to be associated
with higher susceptibility to infection as their frequency did
not differ significantly between patients experiencing hospital
infections/febrile neutropenia compared with patients free of
those complications [MM: 15/114 (13.2%) vs. 18/80 (22.5%, p
= 0.12); LYMPH: 10/82 (12.2%) vs. 4/36 (11.1%, p = 1)]. The
high MBL-conferring genotypes (YA/YA) were associated with
a trend toward more prolonged fever during the neutropenic
period, with 47.1% of patients having fever of more than 4 days
duration being YA/YA, compared with 24.1% having fever for less
than 4 days and 30.1% who had no infection or FN. The LYMPH
group differed from the MM patients in having a high frequency
of the uncommon C allele (codon 57 SNP) (0.025 vs. 0.007 for C;
p= 0.049), but this was not associated with hospital infections.
One hundred and two MM patients were followed-up for at
least 6 months, of which six were hospitalized due to severe
infections. One was O/O and 2 were LXA/O; two of them died.
Other 3 persons (1 non-survivor) had A/A genotypes. Similarly,
from 59 LYMPH patients that were followed-up, three had severe
infections: two were MBL-deficient (O/O; one non-survivor) and
one A/A (survivor).
MBL2 Gene Polymorphisms Located
Within 3′-UTR Region (Exon 4)
Twelve polymorphic sites located within 3′-UTR region of the
MBL2 gene were analyzed. That allowed identification of 27
various genotypes, of which the 7 most common accounted
for nearly 95% of controls and cases (Table 3). The genotype
1 (gt1) was commonest in the C and MM groups, but for the
LYMPH group, genotype 2 was the most frequent. The difference
between LYMPH and C groups with regard to genotype 1 (23.7
vs. 37.2%; p = 0.01) was statistically significant, possibly the first
association of aMBL2 gene 3′-untranslated region polymorphism
with cancer to be observed in Caucasians.
MASP2 Gene Polymorphisms
When the +359 A>G mutation was investigated, no variant
homozygote (and therefore MASP-2/MAp19 deficient) was
found among individuals recruited to the study. The number of
heterozygotes (Table 4) did not differ among the major (C, MM,
LYMPH) groups, although a trend toward higher incidence of
heterozygosity was noted within LYMPH group (Table 4). That
primarily reflected relatively high frequency of A/G genotype
among LYMPH patients who had bacteremia during hospital stay
[8/34 (23.5%); p < 0.04 vs. C group].
For anotherMASP2 SNP,+1111 A>C, no differences between
patients and controls were found. However, this variant allele
was commoner within the LYMPH patients than within the MM
group (p= 0.023) (Table 4).
Serum MBL Concentration and Activity of
Its Complexes With Serine Proteases
The median values determined for samples taken before
chemotherapy did not differ significantly in either MM
(1027 ng/ml; n = 187) or LYMPH (1072 ng/ml; n = 116) groups
when compared with that found for healthy controls (789 ng/ml;
n = 265) (Figure 1). However, the median was higher in MM
patients who later experienced hospital infections (associated or
not with bacteremia) and LYMPH patients who suffered from
infections without bacteremia (Figure 1A).
As was expected from numerous other studies, the median
serum MBL for males and females in the healthy controls were
virtually identical (789 vs. 787 ng/ml), and the higher values
FIGURE 2 | Mannose-binding lectin serum concentrations in healthy controls
carrying most common 3
′
-UTR MBL2 genotypes (gt1-gt4; details are given in
Table 3). Blue bars present median values (given below group descriptions).
TABLE 5 | Serum MBL concentrations in controls and patients (sample 1),
corresponding to most common MBL2 genotypes (basing on 3′-UTR
polymorphisms).
Genotype Group (n) MBL concentration
(ng/ml)
Statistical significance
(vs. C)
Median IQR
gt1 C (93) 1307 683–1969 –
MM (59) 1681 804–2673 p = 0.066
LYMPH (27) 1745 1039–2280 p = 0.12
gt2 C (66) 373 181–1154 -
MM (41) 426 233–1213 p = 0.53
LYMPH (40) 466 188–1479 p = 0.67
gt3 C (47) 858 384–1360 -
MM (39) 1199 976–1858 p = 0.016
LYMPH (28) 1285 880–1875 p = 0.016
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found in the LYMPH group also showed no sex difference (1090
vs. 1054 ng/ml). However, male subjects in the MM group had
significantly higher (1213 vs. 729 ng/ml; p = 0.002) values, and
consequently male MM patients had higher average serum MBL
than male controls (p= 0.032).
Despite well-known association between MBL2 SNP
located within promoter and exon 1 with MBL concentration
(not shown), an influence of exon 4 polymorphisms has
been observed. When the four most common genotypes
were compared within the control group, significant
differences in corresponding median MBL levels were found
(Figure 2). Comparison of patients and controls showed MBL
concentrations significantly higher in patients with genotype 3
for both MM and LYMPH groups (Table 5).
In both MM and LYMPH groups, MBL concentrations
underwent significant changes (p < 0.000001; Friedman’s
ANOVA test) in relation to treatment (Figure 3A). The
changes were generally more evident in persons experiencing
complications during hospital stay (with the exception of
LYMPH patients with bacteremias). (Figure 3A). Data from
samples taken during control examinations (although from
limited number of patients) demonstrated that the concentration
of this lectin ∼100 days post-HSCT practically returns to the
initial (sample 1) value (Figure 4A). In the case of patients
suffering from lymphomas, MBL increased more rapidly than in
those with diagnosedMM, probably depending on chemotherapy
used (BEAM vs. MEL) (Figure 3A). Again, a decrease was
observed after discharge and data from sample 100 were
comparable to those from sample 1 (Figure 4A).
Unexpectedly, very high MBL concentration (>3000 ng/ml)
before treatment seemed to be associated with higher risk of
hospital-acquired infection in MM patients. Such a high level
of the protein was found in 9 of 71 (12.7%) MM patients who
experienced infections, compared with 13 of 265 controls (4.9%;
OR 2.81; p = 0.029). No such relationship was found for the
LYMPH group (8/116 cases, 6.9%). No difference was found in
the frequency of serum MBL deficiency (<150 ng/ml) between
controls (17.7%) and patients (MM: 17.6%; LYMPH: 16.4%).
independently of complications (not shown).
As expected, since correlation coefficients between
serum MBL and activity of its complexes with MASP-1 or
MASP-2 were ≥0.9, the latter activities gave similar results
(Supplementary Figure 1). Moreover, observed MBL variations
in MM patients, slightly but significantly, inversely correlated
with variations in WBC, ANC, PLT counts (changes in leukocyte
counts are demonstrated in Figures 4D–F). In contrast, relatively
strong, positive correlations with concentrations of such markers
of inflammation as CRP or PCT (but not FBG) were found
FIGURE 3 | Changes in concentrations of MBL (A), CL-LK (B), and MASP-2 (C) in patients, during treatment. 1–blood taken directly before conditioning
chemotherapy; 2 – blood taken directly before autologous hematopoietic stem cell transplantation; 3–blood taken 1 week after HSCT; 4—blood taken 2 weeks after
HSCT. Data from sample 5 (3 weeks after HSCT) are not shown due to relatively low number of cases within each subgroup. Median values for each time-point are
presented. MM-A, LYMPH-A: patients who experienced infections with proven bacteremia; MM-B, LYMPH-B: patients who experienced infections with no
bacteremia; MM-C, LYMPH-C: patients who experienced febrile neutropenia; MM-D, LYMPH-D: patients who experienced none of afore-mentioned complications
during hospital stay. C—controls (sampled once). Statistics: given p-values regard to Friedman’s ANOVA while asterisks (in colors corresponding to curves) mark
significant differences in comparison with sample 1 (Wilcoxon’s paired sample test). Graphs show data from complete sets (MBL levels measured in all 1-4 samples)
only. Numbers of patients are given in parentheses.
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FIGURE 4 | Relative (median fold to sample 1) changes in concentrations of MBL (A), CL-LK (B), and MASP-2 (C) and blood morphology: white blood cells (WBC)
count (D), absolute neutrophil count (ANC) (E) and platelet (PLT) count (F) in patients, during treatment. 1—blood taken directly before conditioning chemotherapy;
2—blood taken directly before autologous hematopoietic stem cell transplantation; 3—blood taken 1 week (mean 7.0 ± 0.8 days) after HSCT; 4—blood taken 2
weeks after HSCT (mean 13.6 ± 1.2 days); 5—blood taken 3 weeks after HSCT (mean 20.3 ± 2 days); 45—blood taken 45 days after HSCT (mean 45.3 ± 7.6 days);
100—blood taken 100 days after HSCT (mean 104.1 ± 19.3 days).
(Table 6). It should be mentioned that WBC/ANC/PLT were
checked routinely and regularly (taking samples 1-5 was
coordinated with that) while concentrations of inflammatory
proteins (especially FBG) were tested occasionally, in the case of
morbid indications. Therefore, even relatively high correlation
coefficient not always was associated with statistical significance
(Table 6).
Concentration of CL-LK
The median level of CL-LK in pre-treatment samples from MM
patients (423 ng/ml) was significantly higher than that from
the control group (385 ng/ml; p = 0.0002) (Figure 5A) or the
corresponding samples from LYMPH patients (388 ng/ml; p
= 0.009). This difference did not seem to be associated with
post-HSCT complications. No difference (p = 0.56) was found
between healthy subjects and patients suffering from lymphoma
(Figure 5B).
No significant differences in median CL-LK concentration
between males and females were apparent in MM patients (420
vs. 429 ng/ml) or healthy controls (368 vs. 400 ng/ml). However,
this value was significantly higher in LYMPH group females (430
vs. 371 ng/ml) compared with males (p= 0.004).
The highest CL-LK serum levels (>583 ng/ml) occurred as
frequently among MM patients (7%) and LYMPH patients (6%)
as controls (5.6%). However, low (<242 ng/ml) values were
under-represented within the MM group (2.1%) compared with
the C (5.6%, p = 0.002) or LYMPH (6%, p = 0.037) groups. It
should be stressed that low CL-LK was found in none of the MM
patients experiencing infections or febrile neutropenia (Table 7).
CL-LK concentration during treatment varied, but the
changes noted were not so striking as for MBL. They were
however significant when data from MM patients who suffered
from bacteremia or FN were analyzed (Friedman’s ANOVA: p
< 0.000001 and p = 0.008, respectively) (Figure 3B). Within
LYMPH group, variations were significant for persons affected
by bacteremia only (p= 0.035). The level of CL-LK was generally
lower at point 2 (before HSCT) compared with preceding and
following samples. Interestingly, data from minority of patients
who were sampled during control examinations suggested slight
but significant increase of CL-LK at 45 and 100th days after HSCT
(443 ng/ml; n = 26, p = 0.016 and 457 ng/ml; n = 23, p = 0.048
compared with data from sample 1). In the case of LYMPH, the
median corresponding to samples 100 (384 ng/ml) was similar to
that from samples taken before chemotherapy (Figure 4B).
Described variations were not associated with changes of
blood cell counts or inflammatory markers (Table 6).
An incidental finding was a lack of detectable CL-LK in a
healthy 45-year old woman. A repeat sample 2 months later
yielded only a trace (<40 ng/ml). Sequencing of the COLEC10
gene did not reveal homozygosity for any known variant allele
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TABLE 6 | Correlations (Spearman’s) between variations (samples 1–5) of concentrations/activities of tested proteins/complexes and selected clinical parameters
(significant positive and inverse correlations marked with blue and red, respectively).
Tested factor Blood cell counts Markers of inflammation
WBC ANC PLT CRP FBG PCT
A
MBL r = −0.09 r = −0.11 r = −0.08 r = 0.09 r = 0.07 r = 0.12
p = 0.013 p = 0.002 p = 0.029 p = 0.043 p = 0.63 p = 0.63
n = 792 n = 784 n = 790 n = 518 n = 49 n = 20
MBL-MASP-1 r = −0.09 r = −0.11 r = −0.07 r = 0.08 r = 0.06 r = 0.14
p = 0.015 p = 0.002 p = 0.052 p = 0.09 p = 0.69 p = 0.56
n = 791 n = 783 n = 789 n = 517 n = 49 n = 20
MBL-MASP-2 r = −0.06 r = −0.09 r = −0.07 r = 0.1 r = 0.11 r = 0.12
p = 0.11 p = 0.019 p = 0.072 p = 0.036 p = 0.46 p = 0.61
n = 744 n = 736 n = 743 n = 487 n = 48 n = 20
CL-LK r = −0.08 r = −0.09 r = −0.04 r = 0.1 r = 0.05 r = −0.13
p = 0.022 p = 0.01 p = 0.21 p = 0.025 p = 0.76 p = 0.57
n = 792 n = 784 n = 790 n = 518 n = 49 n = 20
MASP-2 r = −0.1 r = −0.09 r = −0.2 r = 0.2 r = −0.003 r = −0.08
p = 0.004 p = 0.015 p < 0.000001 p = 0.000005 p = 0.98 p = 0.75
n = 790 n = 782 n = 788 n = 516 n = 49 n = 20
B
MBL r = −0.03 r = −0.03 r = −0.09 r = 0.12 r = 0.03 r = 0.35
p = 0.51 p = 0.53 p = 0.06 p = 0.044 p = 0.82 p = 0.015
n = 463 n = 443 n = 462 n = 302 n = 72 n = 48
MBL-MASP-1 r = −0.02 r = 0.002 r = −0.07 r = 0.05 r = 0.06 r = 0.35
p = 0.62 p = 0.97 p = 0.12 p = 0.41 p = 0.65 p = 0.014
n = 462 n = 442 n = 461 n = 301 n = 72 n = 48
MBL-MASP-2 r = −0.005 r = 0.01 r = −0.08 r = 0.1 r = 0.15 r = 0.42
p = 0.92 p = 0.84 p = 0.01 p = 0.071 P = 0.21 p = 0.003
n = 441 n = 421 n = 440 n = 291 n = 71 n = 48
CL-LK r = −0.02 r = 0.01 r = 0.06 r = 0.03 r = 0.05 r = 0.33
p = 0.63 p = 0.77 p = 0.19 p = 0.56 p = 0.65 p = 0.02
n = 463 n = 443 n = 462 n = 302 n = 72 n = 48
MASP-2 r = −0.27 r = −0.27 r = −0.31 r = 0.32 r = 0.13 r = 0.27
p < 0.000001 p < 0.000001 p < 0.000001 p < 0.000001 p = 0.28 p = 0.066
n = 463 n = 443 n = 462 n = 302 n = 72 n = 48
A – patients suffering from multiple myeloma; B – patients suffering from lymphomas.
or “new” mutation when compared to the reference gene
sequence (NCBI Reference Sequence: NC_000008.11, accessed
from: https://www.ncbi.nlm.nih.gov/gene/10584) (not shown).
Concentration of MASP-2
No significant differences were found when pre-treatment
median MASP-2 serum concentrations from MM (357 ng/ml)
or LYMPH (359 ng/ml) were compared with that from healthy
controls (344 ng/ml) (Figure 6). However, a higher value was
observed in the subgroup of MM patients who had infections
with no bacteremia (478 ng/ml, p = 0.017 vs. C group).
Furthermore, median pre-treatment MASP-2 was higher in MM
patients suffering from infections with Gram-positive bacteria
(403 ng/ml) relative to those infected by Gram-negative bacteria
(343 ng/ml; p= 0.008).
Within the control group, a significant sex difference in
median MASP-2 level was found (372 vs. 330 ng/ml for males
and females, respectively, p = 0,019). No such relationship was
found in MM (360 vs. 352 ng/ml) or LYMPH (347 vs. 371 ng/ml)
groups.
When the frequencies of high (>628 ng/ml) MASP-2
concentrations were compared, no significant difference between
the groups was found (C: 5.1%, MM: 6.4%, LYMPH: 2.6%).
Similarly, the incidence of low (<172 ng/ml) MASP-2 was similar
among healthy subjects (10.2%), MM patients (13.4%), and
LYMPH patients (13.8%).
MASP-2 concentrations underwent highly significant
treatment-associated changes in both groups of patients,
independently of complications (Figure 3C). There was again an
increase after treatment, but the kinetics differed from those of
MBL. One and three months after discharge, median MASP-2
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FIGURE 5 | Collectin CL-LK serum concentrations in patients (before
conditioning chemotherapy) and controls. Blue bars present median values
(given below group descriptions). (A) controls (C) vs. multiple myeloma (MM)
patients; (B) controls vs. lymphoma (LYMPH) patients. MM-A, LYMPH-A:
patients who experienced infections with proven bacteremia; MM-B,
LYMPH-B: patients who experienced infections with no bacteremia; MM-C,
LYMPH-C: patients who experienced febrile neutropenia; MM-A, LYMPH-A:
patients who experienced none of afore-mentioned complications during
hospital stay.
concentration in LYMPH patients was still higher than at point
1 (386 ng/ml, n = 40, p = 0.0003 and 419 ng/ml, n = 36, p =
0.006) while for MM group, the difference was insignificant
(Figure 4C).
TABLE 7 | Frequency of low serum concentrations of collectin CL-LK in
investigated groups (for MM and LYMPH groups: data from sample 1, taken
before chemotherapy).
Group (n) % of
concentrations
<242 ng/ml
Statistical
significance
(vs. C)
C (227) 9.7 -
MM (187)* 2.1 p = 0.002; OR 0.2; 95% CI (0.07-0.6)
MM-A (41) 0 p = 0.031; OR 0.11; 95% CI (0.007-1.85)
MM-B (30) 0 p = 0.087
MM-A+B (71) 0 p = 0.003; OR 0.06; 95% CI (0.004-1.07)
MM-C (38) 0 p = 0.052
MM-D (78) 5.1 p = 0.25
LYMPH (116)* 7.8 p = 0.69
LYMPH-A (32) 9.4 p = 1
LYMPH-B (38) 7.9 p = 1
LYMPH-A+B (70) 8.6 p = 1
LYMPH-C (10) 20 p = 0.27
LYMPH-D (36) 2.8 p = 0.22
*MM-A, LYMPH-A: patients who experienced infections with proven bacteremia; MM-B,
LYMPH-B: patients who experienced infections with no bacteremia; MM-C, LYMPH-
C: patients who experienced febrile neutropenia; MM-D, LYMPH-D: patients who
experienced none of afore-mentioned complications during hospital stay.
In both MM and LYMPH groups, MASP-2 correlated
positively with CRP and inversely with WBC, ANC and
PLT counts (Table 6). In contrast to MBL, serum MASP-2
concentrations did not differ between either group of patients
and controls in relation to MASP-2 genotypes (Table 8).
DISCUSSION
Both cancer and its treatment impair immunity, but the role
of MBL and the significance of its deficiency in this context
are controversial since contrasting and apparently contradictory
findings have been reported. Particular attention has focused
on the effect of chemotherapy, both during the immediate
neutropenic period and during longer periods of follow-up. Here
we have demonstrated with a large series of multiple myeloma
patients given similar therapy (and more heterogeneous
lymphoma group), that MBL deficiency has no influence on
the incidence of infections/febrile neutropenia. However, over
a 6-month period of follow-up, MBL deficiency was over-
represented in the small number of patients experiencing
very severe infections. Our findings with a substantially
larger series are not inconsistent with the studies of Molle
et al. (46, 47) with a broadly similar group of myeloma
patients.
These results could be interpreted as meaning MBL
has little influence during the period of chemotherapy-
induced cytopenia (and does not affect post-HSCT recovery
of leukocytes, Supplementary Figure 2), but could have a
protective effect when able to act in combination with
phagocytic cells. That interpretation could explain why for
patients receiving chemotherapy in general, MBL is found
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FIGURE 6 | MASP-2 serum concentrations in patients (before conditioning
chemotherapy) and controls. Blue bars present median values (given below
group descriptions). (A) controls (C) vs. multiple myeloma (MM) patients;
(B)—controls vs. lymphoma (LYMPH) patients. MM-A, LYMPH-A: patients who
experienced infections with proven bacteremia; MM-B, LYMPH-B: patients
who experienced infections with no bacteremia; MM-C, LYMPH-C: patients
who experienced febrile neutropenia; MM-A, LYMPH-A: patients who
experienced none of afore-mentioned complications during hospital stay.
to be effective in studies with a medium to long follow-up
period (48, 49) but ineffective in short-term follow-up studies
(50, 51).
In this study we confirmed the observation of others that
chemotherapy is generally followed by an increase in MBL
concentration (46, 48, 52). We found that after several weeks
it returns to the initial level. A new observation was an
association between MBL deficiency and myeloma itself at the
TABLE 8 | Serum MASP-2 concentrations in controls and patients (sample 1),
corresponding to MASP2 genotypes (+1111 A>C SNP).
Genotype Group (n) MASP-2
concentrations (ng/ml)
Statistical
significance (vs. C)
Median IQR
A/A C (171) 312 238–415 –
MM (120) 320 231–404 p = 0.83
LYMPH (89) 332 233–417 p = 0.86
A/C or C/C C (73) 410 340–513 –
MM (67) 437 335–544 p = 0.46
LYMPH (27) 455 376–506 p = 0.23
genetic level. Furthermore, our data suggest a protective effect
of “gt1” from lymphoma. If and when confirmed, this would
be the first association of a MBL2 gene 3′-untranslated region
polymorphism with cancer in Europeans [those SNPs were
previously reported to have associations with breast or colon
cancer in African-Americans but not in Caucasians (53, 54)].
The influence of 3′-end variant on serum MBL concentration
was originally reported by Bernig et al. (53, 55). They suggested
that Ex4-1067A haplotype corresponds to high MBL. Indeed,
in our study A/A homozygotes (“gt1” genotype) had higher
median than A/G heterozygotes (“gt3”) while, consequently,
heterozygotes (“gt2”) had higher values than G/G homozygotes
(“gt4”) (Figure 2). The Ex4-710/901/1067/1483 SNP were found
to be components of a haplotype block (28, 54, 55). Our data
(Table 3) are in agreement with that finding. Therefore, in
general (although with very few exceptions), analyzing of one
polymorphic site may provide information about the others
(including also Ex4-718/845/879) (Table 3). Interestingly, the
C allele corresponding to Ex4-1483 (associated with Ex4-
1067G) is responsible for interaction with miR-27a, a microRNA
molecule which was suspected to predict lower MBL plasma
concentration (54, 56). Again, it has been to some extent
confirmed here: “gt1” and “gt3” carriers (T/T homozygotes)
have generally higher MBL than “gt2” and “gt4” (T/C genotype)
(Figure 2). Obviously, an interplay between 3′ block and 5′
one (promoter/5′-UTR/exon 1) has to be taken into account in
considering genotype-phenotype relationships (28, 54, 56). For
example, strong linkage disequilibria of Ex4-1067 with promoter
H/L and Y/X SNP were proven [LDmatrix (https://analysistools.
nci.nih.gov) (57)]. It is therefore noteworthy that the majority of
“gt1” genotype carriers (74/95 controls and 61 of 87 patients)
had YA/YA (“high MBL-producing”) genotypes. Interestingly,
the most prevalent 5′ end variant associated with “gt3” was
YA/XA (34/47 controls and 52/69 patients; majority of remaining
individuals carried at least one LXA allele) (not shown). That
altogether confirms apparent links between Ex4-1067A and
promoter (position−221) Y alleles as well as G and X variants,
respectively.
MBL, naturally complexed with MASP has been evidenced
(employing animal model) to contribute to mobilization of
hematopoietic cells from bonemarrow to peripheral blood). That
complex is able to trigger both complement and coagulation
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systems activation, cross-talking in mobilization process (58–
60). It has been suggested that MBL-deficient patients may be
poor HSPC (hematopoietic stem progenitor cells) mobilizers
even upon stimulation for transplantation (58, 59). It however
has not been confirmed in our study: most of MBL deficient
individuals (confirmed by both genotyping andMBL serum level)
responded normally (not shown). It may be speculated that
MBL deficiency is, at least partially, compensated by other lectin
pathway-associated pattern-recognition molecules when MASP
function is normal. Furthermore, it seems not to affect markedly
recovery of leukocytes (at least when their counts recorded at
∼14th day after HSCT, see Supplementary Figure 2).
Another collectin, CL-LK (as mentioned being a complex
of CL-10 and CL-11), was found at higher concentrations
in myeloma patients compared with controls. One and three
months after discharge (samples 45 and 100) its level exceeded
an initial one. However, no clinical significance of extremely
high or low CL-LK was apparent. This is the first possible
association of CL-LK with a hematological malignancy to
have been noted. During hospital stay, CL-LK underwent
marked changes in myeloma patients affected by bacteremia or
febrile neutropenia suggesting involvement of this collectin in
the immune response against some potentially life-threatening
events.
The results of a retrospective study indicated that higher
MASP-2 serum concentrations are associated with a longer
event-free survival (EFS) in children with lymphoma (especially
HL) (61). We have conducted a prospective study, and
collected data from follow up longer than 3–6 months from a
relatively low number of patients. Furthermore most of them
survived that period and had no relapse so our results cannot
easily be compared with the previous report. As with MBL,
higher serum level of its associated serine protease-2 before
chemotherapy seemed to be associated with hospital infections,
at least in MM patients and Gram-positive bacterial agents.
Earlier, MASP2 variant allele (SNP at position +1111) was
suggested to be protective against DLBCL (62). Among 31
DLBCL patients studied here, 7 (22.6%) were heterozygotes
(no difference in comparison to C group). It should however
be stressed that relatively high incidence of MASP2 +359
A/G heterozygosity was noted among LYMPH patients who
experienced bacteremia while relatively low - of +1111 A/C
heterozygosity in LYMPH group in general. Both mentioned
genotypes influence MASP-2 serum concentration (but not
MBL-MASP-2 complex activity when measured as C4 cleaving
potency; not shown). The MASP2 +359G variant abolishes
the formation of the MBL-MASP-2 complex and heterozygotes
present approx. half MASP-2 concentration in serum. However,
this level suffices for full activity of the MBL pathway
(37).
Cancers studied here seem in general to affect concentrations
of complement activating collectins and MASP-2 disparately in
males and females. As previously demonstrated by Troldborg
et al. (63), MBL, CL-10, and CL-11 average levels do not
differ between men and women while MASP-2 is higher in
men. That was fully confirmed here for controls only. Neither
in MM nor LYMPH group the latter differed depending on
sex while MBL was found significantly higher in MM males
compared with females and opposite effect was noted for
CL-LK.
To summarize, we have studied the complex cross-talk
between numerous endogenous and exogenous factors in the
process of treating patients suffering from MM and LYMPH.
Monitoring was started immediately before conditioning
chemotherapy and continued for several weeks. The investigated
factors, involved in activation of the complement and coagulation
cascades, are undoubtedly important players in the events
investigated, influencing disease/treatment course and outcome
and also being influenced by disease itself and therapeutic
procedures. Our data indicate multiple MBL involvements.
We found its primary deficiency to be associated with MM
risk but not hospital infections during cytopenia. Moreover,
high MBL-conferring genotypes and high serum MBL were
to some extent associated with adverse effects. Later, during
follow-up, MBL deficiency seemed to predict higher morbidity
and mortality due to infections. Additionally, we reported
the first possible clinical association of a MBL2 3
′
-UTR
polymorphism (protective effect of “gt1” from lymphoma) in
Caucasians.
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